Zusammenfassung
Hintergrund
Es existieren zahlreiche Systeme zur MRT/TRUS-fusionierten Biopsie der Prostata. Insgesamt liegt ausreichend Literatur zur Fusionsbiopsie vor, die einen Vorteil bei der Tumordetektion und der Diagnosequalität gegenüber der Randombiopsie belegt. Der Nutzen der Systeme im Rahmen der fokalen Therapie des Prostatakarzinoms (PC) ist unklar.
Ziel der Arbeit
Ziel war die kritische Prüfung der vorhandenen Fusionssysteme für die Planung und Verlaufskontrolle einer fokalen Therapie des PC.
Material und Methoden
Es erfolgte eine systematische Literaturrecherche zu den erhältlichen Fusionssystemen für den Zeitraum 2013–5/2016. Durch den Arbeitskreis „Fokale und Mikrotherapie“ wurde ein Kriterienkatalog zu technischen Details, der Eignung in speziellen Situationen und der Eignung im Rahmen der fokalen Therapie des PC erstellt.
Ergebnisse
Acht Fusionssysteme wurden betrachtet (Artemis™, BioJet, BiopSee®, iSR’obot™ Mona Lisa, Hitachi HI-RVS, UroNav und Urostation®). Unterschiede zwischen den Systemen bestehen u. a. in der Art der Biopsie (transrektal, perineal, beides möglich), im Fusionsmodus (starr bzw. elastisch), in der Navigationsart (bildbasiert, elektromagnetisch bzw. mechanisch) sowie im Platzbedarf.
Diskussion
Fusionssysteme werden im Rahmen der fokalen Therapie des PC von verschiedenen Konsensusgruppen empfohlen. Wünschenswerte Eigenschaften sind neben dem „needle tracking“ die Übertragbarkeit des Biopsiedatensatzes in ein Behandlungsgerät (Artemis™, BiopSee® und Urostation®: jeweils mit Focal One®, BiopSee®, Hitachi HI-RVS: jeweils mit Nanoknife®, BioJet und BiopSee®: Kryoablation, Brachytherapie).
Schlussfolgerung
Studien zur Planung einer fokalen Therapie liegen nur für vereinzelte Systeme vor und fehlen für die Verlaufskontrolle nach fokaler Therapie.
Abstract
Background
Several systems for MRI/TRUS fusion-guided biopsy of the prostate are commercially available. Many studies have shown superiority of fusion systems for tumor detection and diagnostic quality compared to random biopsy. The benefit of fusion systems in focal therapy of prostate cancer (PC) is less clear.
Objectives
Critical considerations of fusion systems for planning and monitoring of focal therapy of PC were investigated.
Materials and methods
A systematic literature review of available fusion systems for the period 2013–5/2016 was performed. A checklist of technical details, suitability for special anatomic situations and suitability for focal therapy was established by the German working group for focal therapy (Arbeitskreis fokale und Mikrotherapie).
Results
Eight fusion systems were considered (Artemis™, BioJet, BiopSee®, iSR´obot™ Mona Lisa, Hitachi HI-RVS, UroNav and Urostation®). Differences were found for biopsy mode (transrectal, perineal, both), fusion mode (elastic or rigid), navigation (image-based, electromagnetic sensor-based or mechanical sensor-based) and space requirements.
Discussion
Several consensus groups recommend fusion systems for focal therapy. Useful features are “needle tracking” and compatibility between fusion system and treatment device (available for Artemis™, BiopSee® and Urostation® with Focal One®; BiopSee®, Hitachi HI-RVS with NanoKnife®; BioJet, BiopSee® with cryoablation, brachytherapy).
Conclusions
There are a few studies for treatment planning. However, studies on treatment monitoring after focal therapy are missing.
Literatur
Ahmed HU (2014) Introduction – targeting the lesion, not the organ. Urol Oncol 32:901–902
Baco E, Ukimura O, Rud E et al (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67:787–794
Cash H, Gunzel K, Maxeiner A et al (2016) Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int 118:35–43
Delongchamps NB, Peyromaure M, Schull A et al (2013) Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 189:493–499
Descazeaud A, Rubin M, Chemama S et al (2006) Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World J Urol 24:676–680
Distler F, Radtke JP, Kesch C et al (2016) Value of MRI/ultrasound fusion in primary biopsy for the diagnosis of prostate cancer. Urologe A 55:146–155
Fiard G, Hohn N, Descotes JL et al (2013) Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3‑dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion. Urology 81:1372–1378
Filson CP, Natarajan S, Margolis DJ et al (2016) Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer 122:884–892
Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137
Ho H, Yuen JS, Mohan P et al (2011) Robotic transperineal prostate biopsy: pilot clinical study. Urology 78:1203–1208
Jones JS, Patel A, Schoenfield L et al (2006) Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 175:485–488
Le JD, Tan N, Shkolyar E et al (2015) Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 67:569–576
Mendhiratta N, Rosenkrantz AB, Meng X et al (2015) Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in a consecutive cohort of men with no previous biopsy: reduction of over detection through improved risk stratification. J Urol 194:1601–1606
Meng X, Rosenkrantz AB, Mendhiratta N et al (2016) Relationship between prebiopsy multiparametric Magnetic Resonance Imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol 69:512–517
Miyagawa T, Ishikawa S, Kimura T et al (2010) Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 17:855–860
Mozer P, Roupret M, Le Cossec C et al (2015) First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. BJU Int 115:50–57
Patel AR, Jones JS (2009) Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 19:232–237
Presti JC Jr., O’dowd GJ, Miller MC et al (2003) Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 169:125–129
Radtke JP, Kuru TH, Boxler S et al (2015) Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol 193:87–94
Radtke JP, Schwab C, Wolf MB et al (2016) Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol 70:846. doi:10.1016/j.eururo.2015.12.052
Rud E, Baco E, Eggesbo HB (2012) MRI and ultrasound-guided prostate biopsy using soft image fusion. Anticancer Res 32:3383–3389
Shoji S, Hiraiwa S, Endo J et al (2015) Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. Int J Urol 22:173–178
Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390–397
Tewes S, Hueper K, Hartung D et al (2015) Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results. World J Urol 33:1707–1714
Ukimura O, Hirahara N, Fujihara A et al (2010) Technique for a hybrid system of real-time transrectal ultrasound with preoperative magnetic resonance imaging in the guidance of targeted prostate biopsy. Int J Urol 17:890–893
Valerio M, Ahmed HU, Emberton M et al (2014) The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 66:732–751
Van Den Bos W, Muller BG, Ahmed H et al (2014) Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 65:1078–1083
Vargas HA, Hotker AM, Goldman DA et al (2015) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 26:1606. doi:10.1007/s00330-015-4015-6
Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol 69:16–40
Wysock JS, Rosenkrantz AB, Huang WC et al (2014) A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 66:343–351
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
D. Baumunk, R. Ganzer und A. Blana sind Trainer für die Geräte Ablatherm™ und FocalOne™ und erhalten in dieser Funktion Honorare der Firma EDAP-TMS. M. Schostak und A. Blana sind Berater für EDAP-TMS. B. Hadaschik ist als Berater für MedCom tätig gewesen. T. Franz, J. von Hardenberg, H. Cash, G. Salomon, T. Henkel, J. Herrmann, F. Kahmann, K.-U. Köhrmann, J. Köllermann, S. Kruck, U.-B. Liehr, S. Machtens, I. Peters, J.P. Radtke, A. Roosen, H.-P. Schlemmer, L. Sentker, J.J. Wendler, U. Witzsch, J.-U. Stolzenburg, und geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Die Autoren T. Franz, J. von Hardenberg, M. Schostak und R. Ganzer haben zu gleichen Teilen zum Manuskript beigetragen.
Rights and permissions
About this article
Cite this article
Franz, T., von Hardenberg, J., Blana, A. et al. MRT/TRUS-fusionierte Biopsiesysteme. Urologe 56, 208–216 (2017). https://doi.org/10.1007/s00120-016-0268-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-016-0268-1